| EraGen Biosciences and Illumina announced the formation of a strategic partnership and the execution of non-exclusive licensing agreements. Under these licensing agreements, EraGen Biosciences will have access to Illumina’s BeadXpress platform for the continued development and commercialization of molecular-based, high-throughput clinical multiplexed assays with its unique, patented MultiCode-PLx technology. EraGen has proven commercial success with multiplex molecular assays for the infectious disease and genetic disorder markets. Illumina has licensed EraGen’s MultiCode-PLx technology for the life sciences, research and clinical markets. :theflyonthewall.com |
Subscribe for More Information